Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.

Godman, B; Hill, A; Simoens, S; Selke, G; Selke Krulichová, I; Zampirolli Dias, C; Martin, AP; Oortwijn, W; Timoney, A; Gustafsson, L; Voncina, L; Kwon, H-Y; Gulbinovic, J; Gotham, D; Wale, J; Silva, WCD; Bochenek, T; Allocati, E; Kurdi, A; Ogunleye, OO; Meyer, JC; Hoxha, I; Malaj, A; Hierländer, C; Sauermann, R; Hamelinck, W; Petrova, G; Laius, O; Langner, I; Yfantopoulos, J; Joppi, R; Jakupi, A; Greiciute-Kuprijanov, I; Vella Bonanno, P; Piepenbrink, JH; de Valk, V; Wladysiuk, M; Marković-Peković, V; Mardare, I; Fürst, J; Tomek, D; Obach Cortadellas, M; Zara, C; Pontes, C; McTaggart, S; Laba, T-L; Melien Ø; Wong-Rieger, D; Bae, S; Hill, R

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.

Godman, B Hill, A Simoens, S Selke, G Selke Krulichová, I Zampirolli Dias, C Martin, AP Oortwijn, W Timoney, A Gustafsson, L Voncina, L Kwon, H-Y Gulbinovic, J Gotham, D Wale, J Silva, WCD Bochenek, T Allocati, E Kurdi, A Ogunleye, OO Meyer, JC Hoxha, I Malaj, A Hierländer, C Sauermann, R Hamelinck, W Petrova, G Laius, O Langner, I Yfantopoulos, J Joppi, R Jakupi, A Greiciute-Kuprijanov, I Vella Bonanno, P Piepenbrink, JH de Valk, V Wladysiuk, M Marković-Peković, V Mardare, I Fürst, J Tomek, D Obach Cortadellas, M Zara, C Pontes, C McTaggart, S Laba, T-L Melien Ø Wong-Rieger, D Bae, S Hill, R

Permalink

Publisher:: Informa UK Limited
Publication Type:: Journal Article
Citation:: Expert review of pharmacoeconomics & outcomes research, 2021
Issue Date:: 2021-02-04

Closed Access

	Filename	Description	Size
	PDF EPrint Godman et al March 2021.pdf		990.71 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Godman, B
dc.contributor.author	Hill, A
dc.contributor.author	Simoens, S
dc.contributor.author	Selke, G
dc.contributor.author	Selke Krulichová, I
dc.contributor.author	Zampirolli Dias, C
dc.contributor.author	Martin, AP
dc.contributor.author	Oortwijn, W
dc.contributor.author	Timoney, A
dc.contributor.author	Gustafsson, L
dc.contributor.author	Voncina, L
dc.contributor.author	Kwon, H-Y
dc.contributor.author	Gulbinovic, J
dc.contributor.author	Gotham, D
dc.contributor.author	Wale, J
dc.contributor.author	Silva, WCD
dc.contributor.author	Bochenek, T
dc.contributor.author	Allocati, E
dc.contributor.author	Kurdi, A
dc.contributor.author	Ogunleye, OO
dc.contributor.author	Meyer, JC
dc.contributor.author	Hoxha, I
dc.contributor.author	Malaj, A
dc.contributor.author	Hierländer, C
dc.contributor.author	Sauermann, R
dc.contributor.author	Hamelinck, W
dc.contributor.author	Petrova, G
dc.contributor.author	Laius, O
dc.contributor.author	Langner, I
dc.contributor.author	Yfantopoulos, J
dc.contributor.author	Joppi, R
dc.contributor.author	Jakupi, A
dc.contributor.author	Greiciute-Kuprijanov, I
dc.contributor.author	Vella Bonanno, P
dc.contributor.author	Piepenbrink, JH
dc.contributor.author	de Valk, V
dc.contributor.author	Wladysiuk, M
dc.contributor.author	Marković-Peković, V
dc.contributor.author	Mardare, I
dc.contributor.author	Fürst, J
dc.contributor.author	Tomek, D
dc.contributor.author	Obach Cortadellas, M
dc.contributor.author	Zara, C
dc.contributor.author	Pontes, C
dc.contributor.author	McTaggart, S
dc.contributor.author	Laba, T-L
dc.contributor.author	Melien Ø
dc.contributor.author	Wong-Rieger, D
dc.contributor.author	Bae, S
dc.contributor.author	Hill, R
dc.date.accessioned	2021-03-15T23:33:47Z
dc.date.available	2021-03-15T23:33:47Z
dc.date.issued	2021-02-04
dc.identifier.citation	Expert review of pharmacoeconomics & outcomes research, 2021
dc.identifier.issn	1473-7167
dc.identifier.issn	1744-8379
dc.identifier.uri	http://hdl.handle.net/10453/147183
dc.description.abstract	- CLEAN VERSION <b>Introduction</b>: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. <b>Areas covered</b>: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. <b>Expert commentary</b>: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges including the considerable number of new cancer medicines in development including new gene therapies and being launched with uncertainty regarding their value, continued high prices coupled with the extent of confidential discounts for reimbursement; however, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Informa UK Limited
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1110230
dc.relation.ispartof	Expert review of pharmacoeconomics & outcomes research
dc.relation.isbasedon	10.1080/14737167.2021.1884546
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences, 1117 Public Health and Health Services, 1402 Applied Economics
dc.subject.classification	Health Policy & Services
dc.title	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1117 Public Health and Health Services
utslib.for	1402 Applied Economics
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access	*
dc.date.updated	2021-03-15T23:33:42Z
pubs.publication-status	Published

Abstract:

- CLEAN VERSION Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert commentary: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges including the considerable number of new cancer medicines in development including new gene therapies and being launched with uncertainty regarding their value, continued high prices coupled with the extent of confidential discounts for reimbursement; however, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/147183